Correlation Between Alphabet and CRISPR Therapeutics
Can any of the company-specific risk be diversified away by investing in both Alphabet and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alphabet and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Alphabet Inc Class C and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Alphabet and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alphabet with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alphabet and CRISPR Therapeutics.
Diversification Opportunities for Alphabet and CRISPR Therapeutics
-0.12 | Correlation Coefficient |
Good diversification
The 3 months correlation between Alphabet and CRISPR is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding Alphabet Inc Class C and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Alphabet is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alphabet Inc Class C are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Alphabet i.e., Alphabet and CRISPR Therapeutics go up and down completely randomly.
Pair Corralation between Alphabet and CRISPR Therapeutics
Given the investment horizon of 90 days Alphabet Inc Class C is expected to under-perform the CRISPR Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Alphabet Inc Class C is 2.05 times less risky than CRISPR Therapeutics. The stock trades about -0.14 of its potential returns per unit of risk. The CRISPR Therapeutics AG is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest 3,159 in CRISPR Therapeutics AG on December 24, 2024 and sell it today you would lose (219.00) from holding CRISPR Therapeutics AG or give up 6.93% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 98.33% |
Values | Daily Returns |
Alphabet Inc Class C vs. CRISPR Therapeutics AG
Performance |
Timeline |
Alphabet Class C |
CRISPR Therapeutics |
Alphabet and CRISPR Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Alphabet and CRISPR Therapeutics
The main advantage of trading using opposite Alphabet and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alphabet position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.The idea behind Alphabet Inc Class C and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.CRISPR Therapeutics vs. JB Hunt Transport | CRISPR Therapeutics vs. Beyond Meat | CRISPR Therapeutics vs. Cognizant Technology Solutions | CRISPR Therapeutics vs. Marvell Technology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Complementary Tools
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |